INTRODUCTION:

The Pharmacovigilance word is originated from Greek word “pharmacon” and “vigilare” means “drug” and “to keep watch”, respectively¹. In 2002, WHO characterizes the science and exercises identifying with the detection, evaluation, comprehension and avoidance of unwanted impact or any medication related issue². There are 134 countries part of WHO’s Pharmacovigilance programme in 2010, which upgrade the collaboration between central and international drug monitoring. Adverse drug reaction observing centers initiated in India in 1986. Initially it was started with more than ten provincial centers.

At arrangement six territorial places (Kolkata, New Delhi, Mumbai, Lucknow, Pondicherry, Chandigarh) were hoist for the purpose of the overlooking of ADR system in this country. Only New Delhi and Mumbai are active for reporting of ADRs center while other center reports are unconstrainedpoor³. At beginning there are 22 AMCs in the country. The number has been increased into almost one hundred and fifty that has been circulated in four territories^4-7

Pharmacovigilance (PV) was correctly initiated in December 1961 giving of a case report in the lancet by W. McBride⁸. Thousands of babies are born without limb because subjection to thalidomide ingested by the pregnant women for morning sickness its adverse effect on babies in utero.1^st time, systematically bash were compel globally to deal with the pandemic situation of adverse effect of drug and patient security⁹. In India, PV is organized by IPC- Indian pharmacopeia commission and administered by by the central drug standard control organization. ADR are the 5^thmost usual aspect of hospital death and 4^th most ordinary aim of morbidity in the world 3.7% of the case are admitted in the hospital are cause of ADR, 1.8% are fetal¹⁰. India is a 2^nd incomparable territory along with one billion potential drug consumers. India is contributing a small role to the Uppsala monitoring centre program (UMCP) in distribution of data base relatives. This data base is crucial for the vigorous adverse drug effect and beside absence of consciousness of reporting concept of Indian health care profession. In India it is tremendously necessary to focus the attentiveness of the medical community on the reporting of adverse drug reaction (ADR) and to make sure utmost welfare to the public health and their safety¹. The present write up focused on pharmacovigilance programme in India, its present status and future prospect with the reference to its impact on COVID 19.

Objectives of Pharmacovigilance:

PV has a vital role in the assessment of adverse effects induced by the drugs whether it is catalyzed by oral drugs; parenteral drugs or I.V. drugs. These drugs are pretested for ADRs before it is being marketed worldwide. PV is an important aspect to detect and identify the adverse effects arise from the use of the drugs. But to fulfil these requirements of finding and eliminating, a side effect is the responsibility of the doctors involved in the case; nurses, health workers, residents and proper guidance of the patients themselves help it to alleviate the root cause of ADR^11,12. The aim of PV has been mentioned in Fig, 1.

Some other objectives of Pharmacovigilance are:-

To improve patient consideration and security according to the utilization of prescriptions and every premedical intercession, To improve general wellbeing and security corresponding to the utilization of medications, To add to the evaluation of advantage, hurt, adequacy, and hazard of meds, empowering their protected, objective and more successful use, To advance arrangement, schooling, and clinical preparing in Pharmacovigilance and its compelling correspondence to wellbeing experts and the general population^9,13

Fig 1: Aim of PV

Pharmacovigilance Program in India:

History of PvPI:

The idea of PV is moving from the past, because the hour of Charaka Samhita in 700 BC had admonished that fittingly saw, improperly coordinated medicine is somewhat of a poisonous substance and Vagbhatta a specialist tended to unfavorable occasion, reason, deferred ADRs to Ayurvedic Drugs' around 500 AD. Thereafter, numerous reports of ADRs from India territory unit found within the history of modern medicine but there was no systematic effort of ADR monitoring since the primary try was created in 1989⁹.

The foundation of a perceived Pharmacovigilance framework in India was first proposed in the year 1986, when a formal Adverse medication response (ADR) including 12 provincial places, each taking into account a populace of 50 million individuals, was proposed. However, not a lot occurred until 10 years after the fact when in 1997, India joined the WHO's ADR Monitoring Program situated in Uppsala, Sweden^14.The Uppsala Monitoring Centre (UMC) was set up with the target of keeping a worldwide data set of suspected ADR reports. In India, six centres were recognized and set up with respects to this, in particular in New Delhi, Lucknow, Chandigarh, Mumbai, Pondicherry and Kolkata.However, out of these six centres, only the National Pharmacovigilance Center at AIIMS, New Delhi and two WHO monitored centres in Mumbai (KEM Hospital and JLN Emergency clinic) were dynamic and in this manner unconstrained announcing of ADR's was poor².

The monitoring centres were viewed as impromptu and fitting degrees of subsidizing were not, made accessible, which put serious requirements on them. Perceiving the requirement for improved ADR checking in India, the Govt. of India sent a proposition to the World Bank for financing. The World Bank endorsed the proposition with a yearly award of US$0.1 million for a very long time and the National Pharmacovigilance Program (NPVP) was dispatched in November 2004.The NPVP was directed by the National Pharmacovigilance Advisory Committee situated in the CDSCO, New Delhi. Two zonal focuses - the South-West Zonal centre (situated in the Dept. of Clinical Pharmacology, Seth GS Medical College and KEM Hospital, Mumbai) and the North-East Zonal centre (situated in the Dept. of Pharmacology, AIIMS, New Delhi), gathered data from everywhere the country and send it to the Committee just as to the UMC in Sweden¹⁵.

Current scenario of PvPI:

India is a massive country and there are medication marks in excess of 6,000 authorized medication makers and more than 0.6 lakh branded formulations. India is the fourth driving maker of drugs in the world and is additionally arising as a center for clinical preliminaries. Numerous most recent medications are being presented in the country, so there is a tremendous need to propel the Pharmacovigilance framework to shield the Indian populace from potential damage that might be brought about by different new medications¹⁶.

The National Pharmacovigilance Program was officially inaugurated by the Honourable Health Minister Dr. Anbumani Ramadoss on 23^rd November, 2004 at New Delhi. The situation of the drug specialist inside the medical services framework has ceaselessly been dependent upon conversation and change. The pharmacist's essential mission traditionally has been to administer drugs as endorsed by a doctor and to guarantee that these medications fulfill the necessary guidelines. These days the drug specialist additionally every now and again goes about as a consultant on pharmacotherapy. In the UK and US, pharmacists are, to a degree, also authorized to write out prescriptions, which incidentally has been a long-standing practice in countries reported with shortage of doctors^17-19.

The CDSCO, New Delhi, under the aegis of the Ministry of Health and Family Welfare, Government of India has started a cross country Pharmacovigilance program in July 2010. The Pharmacovigilance Program of India (PvPI) was dispatched with an expansive goal to shield the strength of 1.27 billion individuals of India. Unfriendly Drug Reactions (ADRs) are accounted for from everywhere the country to National Coordination Center (NCC) - PvPI, which additionally works in a joint effort with theworldwide ADR monitoring, Sweden. To screen ADRs and revealing something similar to NCCPvPI, ADR Monitoring Centers (AMCs) have been set up all over India. At present 250 AMCs (clinical schools, locale and corporate emergency clinics and so forth) are enlisted under PvPI the nation over^20-21.

Scope of PvPI:

Prior to enlistment and selling of medications inside the nation, its wellbeing and usefulness expertise area unit fundamentally should be based completely on the work of the medications in clinical preliminaries. Some essential responses, similar to those, that set aside an extended effort to create, or those, that happen only from time to time, probably won't be distinguished in clinical preliminaries. Along these lines, to accomplish an exhaustive security profile of medications, a nonstop post-advertising observing framework for example PV is essential^9,22.

In the long run, Pharmacovigilance tackles with two main problems. First is the identification of hazards related with pharmaceutical products and the second is to minimise the risk of any harm, if caused by those drugs. In spite of being a recently discovered field of exploration and study, the Pharmacovigilance market is extending around the world at a fast since it is viewed as an imperative for clinical examination. In the year 2013, it was assessed to be a USD 2,408.0million market all around the world while it is relied upon to develop at 14.20% CAGR somewhere in the range of 2014 and 2020. According to a report by Transparency Market Research recommends that the Pharmacovigilance market is required to arrive at US$6.1 bn by 2020. The fundamental purposes behind the expansion of the Pharmacovigilance market are the exacting medication security guidelines and strategies by the administrations of generally created and agricultural nations and an always expanding frequency pace of ADR (adverse drug reactions) which has ended up being a gigantic risk on medical services frameworks and furthermore represents an enormous number of passing consistently²³.

Present status of PvPI:

Numerous new medications are being presented in the country, so there is a need to improve the Pharmacovigilance framework to shield the Indian populace from potential mischief that might be brought about by a portion of the new medications. In any case, there are various issues and issues that have forestalled fabricating a powerful Pharmacovigilance framework, which are described below^1,11.

1. Pharmacovigilance frameworks are not well funded and organized for a tremendous nation like India to serve patients and the general population.

2. The information got to date in the zonal focuses from different fringe habitats is frequently poor and not well analyzed. There is deficient examination on ADRs in India, so the specific rate of explicit ADRs is obscure²⁴.

3. Contribution of medical services experts (both in provincial territories and metropolitan urban communities and emergency clinics) and information and inspiration for Pharmacovigilance is insignificant. There little support from the branch of wellbeing to give really preparing and make more mindfulness among them for better detailing.

4. In India, there are a few consumers group who urge patients to report any antagonistic responses experienced by them, despite the fact that there is no data for patients to report ADRs straight forwardly to the administrative power^25-26.

Future aspects of PvPI:

An appropriately functioning pharmacovigilance system is vital if drugs are to be used with safety. It will provide advantage for all parties including healthcare professionals, regulatory authorities, pharmaceutical companies and the consumers. It assists pharmaceutical companies to continuously monitor their drugs for threat and to devise and implement the effective threat management plans to save their medicines in difficult situations^27,28.

The following proposals ability is as follows

1. Building and keeping a powerful Pharmacovigilance framework.

2. Making Pharmacovigilance announcing obligatory and presenting Pharmacovigilance investigations time to time without suggestions.

3. Undeniable level conversations with different grouped work force.

4. Fortify of the DCGI office with prepared logical and clinical assessors for Pharmacovigilance.

5. Making an individual country-explicit unfriendly occasion announcing structure to be accustomed by all.

6. Making a particular clinical preliminary and post showcasing information base for SAEs/SUSARs and ADRs for signal recognition and admittance to all understanding information from different partners.

7. Training and education of medical students, pharmacists and nurses in the area of Pharmacovigilance²⁷.

The PV could assume a part in individual threat factors for the happening of certain ADRs. Later on, PV needs to focus on the patients as a wellspring of data notwithstanding the more customary gatherings, like the wellbeing experts. As of now, the DCGI should act rapidly to improve PV in order to incorporate Good Pharmacovigilance Practice (GPP) into the cycles and strategies to help guarantee administrative consistence and upgrade clinical preliminary security and post advertising observation. A suitably working PV framework is fundamental if meds are to be utilized cautiously. It will profit medical services experts, administrative specialists, drug organizations and the customers. It assists drug organizations with observing their medications for hazard. Post-marketing PV is right now a difficult and arduous cycle, not only industry-wide, but also for regulatory agencies^29,30.

PvPI IN COVID-19:

Monitoring vaccine safety feasible by active and passive both surveillance. The primery purpose of the vaccine pharmacovigilance program is to assure and secure the safety of vaccine dose recipients. The most of the countries have a strong vaccine pharmacovigilance program. The primary objective of vaccine pharmacovigilance during anti-COVID-19 vaccination is the timely detection and appropriate response to any suspected adverse events associated with vaccination^31,32.

A large number of population across the world are vaccinating in a short time period. It may become very hard to follow them up and aggregate any of the suspected adverse events occurring following vaccination unless all stakeholders pull up their shocks and work in tandem. Appropriate information regarding the reactions adversity of the post vaccination used against COVID-19 is highly essential, and it is critical that all adverse reactions are carefully recorded and the same is reported as quickly as possible so that remedial step can be promptly taken. This will not only help in safeguarding the health of vaccine recipients but also allay the unnecessary scepticism about COVID-19 vaccination. International collaboration and sharing of data between national agencies helming the vigilance program is necessary during a crisis of this proportion as it will enable in disseminating information against any suspected adverse reaction reported and help in restricting its unfortunate outcomes in a majority of the population^31,33.

The above discussions is suggesting that pharmacvigilance has its importance in many spheres of health system and adverse drug reaction reporting is also an important topics to be considered^30-31,33-36.

CONCLUSION:

India has the more than 500000 qualified Doctors and 6,24,000 beds over 15,000 Hospitals. India is the fourth biggest pharmaceutical manufacturer in the world. The country has claimed worldwide as a significant Clinical trials centre. It is emerging as an important Clinical trial hub in the world. Many new drugs are being introduced in our country. Hence, there is a requirement for a dynamic pharmacovigilance framework in the nation to shield the populace from the potential damage that might be brought about by a portion of these new medications. Pharmacovigilance has not gotten well in India and the subject is in its outset. India rates underneath 1% in pharmacovigilance as against the world pace of 5%. This is because of obliviousness of the subject and furthermore absence of preparing. The PvPI, in its 8-year spell up until this point, has bloomed and formed into an element that has become an imperative piece of the whole drug arrangement of India. It has helped draw the consideration of the medical services local area just as the overall population towards drug-related occasions and proposed adjustments in different therapies that are pointed toward profiting the patients.

ABBREVIATIONS:

WHO: World Health Organization; CDSCO: Central Drugs Standard Control Organization; PvPI: Pharmacovigilance Programme of India; NCC: National Coordinating Centre; AIIMS: All India Institute of Medical Sciences; IPC: Indian Pharmacopoeia Commission; PV: Pharmacovigilance; ADR: Adverse Drug Reaction; AMC: ADR Monitoring Centre; UMC: Uppsala Monitoring Centre.

ACKNOWLEDGEMENT:

The authors are very thankful to the director and management of NIMS University, Rajasthan and Divine Group of Institutions, Bihar for their continuous effort and support.

CONFLICT OF INTEREST:

The authors do not have any conflict of interest. The write up is not funded by any sources.

REFERENCES:

1. Kumar DA. Reddenna L. Basha SA. Pharmacovigilance Programme of India. Research & Reviews: A Journal of Pharmacology. 2014; 4(3):13-23.

2. Fernandes SD. Anoop NV. Castelino LJ. Charyulu RN. A national approach to pharmacovigilance: The case of India as a growing hub of global clinical trials: Research in Social and Administrative Pharmacy. 2019; 15(1):109-13. doi.org/10.1016/j.sapharm.2018.03.061

3. LihiteJ.Ratan and Lahkar Mangala. An update on the Pharmacovigilance Program of India. Frontiers in Pharmacology.2015; 6(194) doi.org/ 10.3389/fphar.2015.00194

4. Suke SG. Kosta P. Negi H. Role of pharmacovigilance in India: An overview. Online Journal of Public Health Informatics. 2015; 7(2). doi.org/10.5210/ojphi.v7i2.5595

5. Shraddha Anil Naik. Review on Pharmacovigilance. Asian J. Pharm. Res. 2020; 10(2):123-28.doi.org/10.5958/2231-5691.2020.00024.6

6. Adamu Yau.Nordin Bin Simbak. Mainul Haque. Pharmacogenovigilance: A Potential Tool in Pharmacovigilance. Research J. Pharm. and Tech. 7(12): 2014; 1476-82

7. Hailye Birhane.Mojahidul Islam. Damen H mariam. Vijender Singh. Pharmacovigilance: Adverse Drug Reactions (ADRs) in Pediatric patients in Ethiopia. Retrospective Study. Research J. Pharm. and Tech 2021; 14(3):1499-1506. DOI: 10.5958/0974-360X.2021.00266.3

8. Kalaiselvan.V.Srivastava. Singh Abhishank. Gupta SK. Pharmacovigillance program in India: Present scenario and future challenges. Archives of Pharmacy Practice. 2018; doi.org/10.1007/s40264-018-0730-7

9. Nimesh Saurabh.Chaudhary Anurag. Sharma Anjana and Kapil Dev Negi.Pharmacovigillance program of India: A review.Acta Scientific Pharmaceutical Sciences. 3.9(2019): 12-17.

10. Gadhade B.Jyoti. HirayS.Rajesh. Aherkar .Y Rekha .Kalpana U.Shah.Pharmacivigillance program of India: revival of the renaissance. International Journal of Basic and Clinical Pharmacology. 2018; doi.org/10.18203/2319-2003.ijbcp20184338

11. Rajgopal Jk. Shilpi K. Ak S. Pharmacoviglance: A Review Article. Innovare Journal of Medical Sciences.2016; 2321-4406.

12. Danan G. Benichou C. Causality assessment of adverse reactions to drugs—I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. Journal of Clinical Epidemiology. 1993; 46(11):1323-30.doi.org/10.1016/0895-4356(93)90101-6

13. Lal D.Manocha S. Ray A.Vijayan VK. Kumar R. Comparative study of the efficacy and safety of theophylline and doxofylline in patients with bronchial asthma and chronic obstructive pulmonary disease. Journal of Basic and Clinical Physiology and Pharmacology. 2015; 26(5):443-51.doi.org/10.1166/jmihi.2020.3055

14. Kumar A. Past, present and future of pharmacovigilance in India. Systematic Reviews in Pharmacy. 2011; 2(1):55.

15. Gupta YK. Ensuring patient safety-launching the new pharmacovigilance programme of India. Pharma Times. 2010; 42(8):21-6.

16. Simha Haripriya.Marisarla Syamala. Mujeebuddin S.C. Pharmacovigilance system in India. International Journal of Pharmaceutical Sciences. 2020; 63(1): 73-80.

17. Ghewari PS. Salunkhe SS. Bhatia NM. Killedar SG. Chitranagari K. Strategies and current scenario of pharmacovigilance in India. Journal of Advanced Drug Delivery. 2014; 1(3):122-34.

18. Van Grootheest K. Olsson S. Couper M. de Jong‐van den Berg L. Pharmacists' role in reporting adverse drug reactions in an international perspective. Pharmacoepidemiology and Drug Safety. 2004; 13(7):457-64.doi.org/10.1002/pds.897

19. Clause S. Fudin J. Mergner A. Lutz JL. Kavanaugh MM. Fessler K. Chirumamilla S. Prescribing privileges among pharmacists in Veterans affairs medical centers. American Journal of Health-System Pharmacy. 2001; 58(12):1143-5.

20. Anirudhprasad Kancharla.Current scenario of pharmacovigilance in India and its comparison with U.S.A and E.U.The Pharma Innovation Journal.2019; 8(6): 302-7.

21. Recast EP. Directive 2010/31/EU of the European Parliament and of the Council of 19 May 2010 on the energy performance of buildings (recast). Official Journal of the European Union. 2010; 18(06):2010.

22. Bester K.Meyer H. Crowther M. Gray R. Anaesthesia for paediatric patients: Minimising the risk. South African Medical Journal. 2018; 108(6):457-9.

23. Scope of Pharmacovigilance in India – An Industry of Drug Safety, Business Alligators, Available from: https://www.businessalligators.com/scope-pharmacovigilance-india-industry-drug-safety/, last updated on: 9th Dec, 2016.

24. Guideline IH. Post-approval safety data management: definitions and standards for expedited reporting E2D. Published in the Federal Register. 2003; 68(178):53983-4.

25. Vivekanandan K. Prakash J. Singh GN. Pharmacovigilance programme of India. Archives of Pharmacy Practice. 2012; 1; 3(3):229.

26. Kalaiselvan V. Kumar R. Singh GN. Indian Pharmacopoeia commission's partners for promoting public health. Adv Pharmacoepidemiol Drug Saf. 2015; 4(181):2167-1052. doi.org/10.4172/2167-1052 .1000181

27. Aswath N, VT H. Pharmacovigilance, Adverse Drug Reactions and Future Aspects of Pharmacovigilance in India: A Review Article. Indian Journal of Public Health Research & Development. 2019; 1; 10(12).

28. World Health Organization. "A public health approach for scaling up antiretroviral (ARV) treatment: a toolkit for programme managers." (2003).

29. Sawarkar A. Sharma RK. Gautam V. Shramankar K. Dinodia N. Pharmacovigilance: Present status and future perspectives. The Pharma Innovation Journal. 2019; 8(8):84-92.

30. Ghewari PS, Salunkhe SS, Bhatia NM, Killedar SG, Chitranagari K. Strategies and current scenario of pharmacovigilance in India. Journal of Advanced Drug Delivery. 2014; 1(3):122-34.

31. Meher B. Need of vibrant vaccine pharmacovigilance during current global COVID-19 pandemic: More than ever. Journal of Pharmacy and Bioallied Sciences.2021;13(1):1. doi: 10.4103/jpbs.JPBS_416_20

32. World Health Organization. "Causality assessment of an adverse event following immunization (AEFI): user manual for the revised WHO classification." (2018).

33. Daley MF. Narwaney KJ. Shoup JA. Wagner NM. Glanz JM. Addressing parents’ vaccine concerns: a randomized trial of a social media intervention. American Journal of Preventive Medicine. 2018; 55(1):44-54.doi.org/10.1016/j.ampere.2018.04.010

34. Hailye Birhane. Mojahidul Islam. Damen H/mariam. Vijender Singh. Pharmacovigilance: Adverse Drug Reactions (ADRs) in Pediatric patients in Ethiopia. Retrospective Study. Research J. Pharm. and Tech 2021; 14(3):1499-1506. DOI:10.5958/0974-360X.2021.00266.3

35. Farah Hamad Farah. Pharmacovigilance Implications of some inactive Pharmaceutical Ingredients. Research J. Pharm. and Tech. 2020; 13(11):5493-5496. DOI:10.5958/0974-360X.2020.00959.2

36. Yaser M. Al Worafi, Sanah Hasan, Nageeb M. Hassan, Ahmed A. Gaili. Knowledge, Attitude and Experience of Pharmacist in the UAE towards Pharmacovigilance. Research J. Pharm. and Tech. 2021; 14(1):265-269. DOI:10.5958/0974-360X.2021.00047.0

Received on 27.07.2021 Modified on 09.01.2022

Asian J. Res. Pharm. Sci. 2022; 12(3):205-209.

DOI: 10.52711/2231-5659.2022.00036